NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Polaris Peptides

Published 12 Nov 2026. 26-page investigative report on who is behind Polaris Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 107 Finnrick lab tests, Polaris Peptides shows 66 pass / 33 fail for an overall pass rate of 62%. The brand average hides a split catalog: tirzepatide and retatrutide are the more defensible Polaris choices, while BPC-157 is the clearest avoid signal and CJC-1295 remains weak on a thinner record. The full report shows why ratings contract under stricter scoring rather than treating the brand as one uniform quality level.

Public records support a real U.S. operator rather than a faceless clone: Polaris Peptides traces to Polaris Bioactives LLC in Nevada, a related Washington entity, and a named U.S. controller. But the buyer-facing perimeter is messy. The canonical .com is now members-only while public APIs expose a sizeable product and COA archive; a Polaris-branded .io store shares enough identifiers to look probable, but lacks a clean official cross-link.

Beyond the testing, the investigation maps a live typosquat, suspended lookalikes, downstream sites hosting Polaris COAs, payment-method contradictions, and a large multi-lab COA archive with vendor-submitted sampling, label-mismatch flags, and endotoxin-coverage gaps. Personnel review finds identifiable commercial control, but not a public QA or batch-release chain; the report distinguishes external-lab evidence for submitted samples from unresolved sourcing and release controls.

Inside the full report:

  • Per-product Finnrick pass/fail rates, methodology-divergence charts, and Appendix A laboratory data for all 9 tested products
  • Nevada and Washington corporate filings tying Polaris Peptides, Polaris Bioactives LLC, Evergreen Research Supply LLC, and the Maring records
  • Storefront-authentication map covering the gated .com, probable-but-unconfirmed .io store, live typosquat, and suspended lookalikes
  • COA archive review across TrustPointe, Accumark, Chromate, BTLabs, and Janoshik, including label and safety-panel gaps
  • Checkout, payment-rail, privacy, complaint, reseller, and fulfillment-address analysis

Risk assessment

  • BPC-157 product-quality risk — high: BPC-157 is 4 pass / 12 fail across 16 Finnrick tests with a 35.18% rating; it is the clearest avoid signal in the Polaris catalog.
  • CJC-1295 product-quality risk — medium: CJC-1295 has only 4 Finnrick tests, 2 pass / 2 fail, and a 32.44% rating; the sample is thin but weak.
  • Copycat and channel-authenticity risk — high: The canonical .com is gated, .io is probable but unconfirmed, and a live typosquat plus historical lookalikes create real mispurchase risk.
  • Non-reversible payment and remedy risk — medium: The observed .io checkout offered crypto, bank transfer, cheque/COD, and manual cash rails while terms advertised mainstream methods.
  • COA and safety-panel verification risk — medium: The archive is large but vendor-submitted; third-party review flags 15 label mismatches and limited endotoxin coverage, so lot verification matters.